| Literature DB >> 24648342 |
Nicole L Yates1, Hua-Xin Liao, Youyi Fong, Allan deCamp, Nathan A Vandergrift, William T Williams, S Munir Alam, Guido Ferrari, Zhi-yong Yang, Kelly E Seaton, Phillip W Berman, Michael D Alpert, David T Evans, Robert J O'Connell, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B Gilbert, Gary J Nabel, Nelson L Michael, Jerome H Kim, David C Montefiori, Barton F Haynes, Georgia D Tomaras.
Abstract
HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24648342 PMCID： PMC4116665 DOI： 10.1126/scitranslmed.3007730
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956